Following the launch of GenoVic last year, the organization is working to get more centers on the platform and figure out its role in an A$500M national initiative.
An Australian research team found that population genetic screening for hereditary cancer and for carrier status could be cost-effective.
The MammaSeq assay comprises 79 genes and 1,369 mutations in breast cancer that could be used as potential downstream therapeutic targets.
The American Society of Breast Surgeons updated consensus guidelines to recommend multigene panel testing for patients with cancer, including those who were tested many years ago.
The team plans to launch an RNA-seq diagnostic test out of the SickKids clinical laboratory in one year to complement clinical exome sequencing.